Francisco Javier Marquez Gomez

List of Publications by Year
in descending order

95 papers	4,806 citations	87723 38 h-index	98622 67 g-index
98 all docs	98 docs citations	98 times ranked	5917 citing authors

#	Article	IF	Citations
1	Glutaminase isoforms expression switches microRNA levels and oxidative status in glioblastoma cells. Journal of Biomedical Science, 2021, 28, 14.	2.6	11
2	Antioxidant responses related to temozolomide resistance in glioblastoma. Neurochemistry International, 2021, 149, 105136.	1.9	17
3	Tumor Metabolome: Therapeutic Opportunities Targeting Cancer Metabolic Reprogramming. Cancers, 2021, 13, 314.	1.7	2
4	Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer. Seminars in Cell and Developmental Biology, 2020, 98, 34-43.	2.3	84
5	Glutaminases regulate glutathione and oxidative stress in cancer. Archives of Toxicology, 2020, 94, 2603-2623.	1.9	38
6	Nuclear Translocation of Glutaminase GLS2 in Human Cancer Cells Associates with Proliferation Arrest and Differentiation. Scientific Reports, 2020, 10, 2259.	1.6	26
7	Metabolic Reprogramming of Cancer by Chemicals that Target Glutaminase Isoenzymes. Current Medicinal Chemistry, 2020, 27, 5317-5339.	1.2	26
8	The Epithelial to Mesenchymal Transition Promotes Glutamine Independence by Suppressing GLS2 Expression. Cancers, 2019, 11, 1610.	1.7	31
9	Dysregulation of glutaminase and glutamine synthetase in cancer. Cancer Letters, 2019, 467, 29-39.	3.2	107
10	Transfection with GLS2 Glutaminase (GAB) Sensitizes Human Glioblastoma Cell Lines to Oxidative Stress by a Common Mechanism Involving Suppression of the PI3K/AKT Pathway. Cancers, 2019, 11, 115.	1.7	17
11	Lysophosphatidic Acid and Glutamatergic Transmission. Frontiers in Molecular Neuroscience, 2019, 12, 138.	1.4	16
12	A Distinct Metabolite Profile Correlates with Neurodegenerative Conditions and the Severity of Congenital Hydrocephalus. Journal of Neuropathology and Experimental Neurology, 2018, 77, 1122-1136.	0.9	4
13	Glutaminase isoenzymes in the metabolic therapy of cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 158-164.	3.3	63
14	Glutamine Addiction In Gliomas. Neurochemical Research, 2017, 42, 1735-1746.	1.6	64
15	Glutamate and Brain Glutaminases in Drug Addiction. Neurochemical Research, 2017, 42, 846-857.	1.6	35
16	Glutaminase and MMP-9 Downregulation in Cortex and Hippocampus of LPA1 Receptor Null Mice Correlate with Altered Dendritic Spine Plasticity. Frontiers in Molecular Neuroscience, 2017, 10, 278.	1.4	14
17	Glutaminases. Advances in Neurobiology, 2016, 13, 133-171.	1.3	23
18	Pharmacological Blockade of Cannabinoid CB1 Receptors in Diet-Induced Obesity Regulates Mitochondrial Dihydrolipoamide Dehydrogenase in Muscle. PLoS ONE, 2015, 10, e0145244.	1.1	31

#	Article	IF	Citations
19	Glutaminases in brain: Multiple isoforms for many purposes. Neurochemistry International, 2015, 88, 1-5.	1.9	17
20	Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nature Medicine, 2015, 21, 1182-1189.	15.2	180
21	Expression of Gls and Gls2 glutaminase isoforms in astrocytes. Glia, 2015, 63, 365-382.	2.5	45
22	Canceromics Studies Unravel Tumorâ€™s Glutamine Addiction After Metabolic Reprogramming. , 2015, , 257-286.		5
23	Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells. Journal of Molecular Medicine, 2014, 92, 277-290.	1.7	74
24	Silencing of GLS and overexpression of GLS2 genes cooperate in decreasing the proliferation and viability of glioblastoma cells. Tumor Biology, 2014, 35, 1855-1862.	0.8	44
25	Self-condensation of Î²-(isoxazol-5-yl) enamines under treatment with acetyl chloride and acids. Synthesis of novel 1,3-diisoxazolyl-1,3-dieneamines and 1,3,5-triisoxazolyl benzenes. Tetrahedron, 2014, 70, 3915-3923.	1.0	5
26	Glutamine, Glucose and other Fuels for Cancer. Current Pharmaceutical Design, 2014, 20, 2557-2579.	0.9	29
27	Mammalian glutaminase isozymes in brain. Metabolic Brain Disease, 2013, 28, 133-137.	1.4	14
28	Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress Against Cancer. Current Molecular Medicine, 2013, 13, 514-534.	0.6	161
29	Oxidative stress in apoptosis and cancer: an update. Archives of Toxicology, 2012, 86, 1649-1665.	1.9	290
30	An electrophoretic approach to screen for glutamine deamidation. Analytical Biochemistry, 2012, 428, 1-3.	1.1	6
31	Mammalian Glutaminase Gls2 Gene Encodes Two Functional Alternative Transcripts by a Surrogate Promoter Usage Mechanism. PLoS ONE, 2012, 7, e38380.	1.1	44
32	Sulphur-containing non enzymatic antioxidants therapeutic tools against cancer. Frontiers in Bioscience - Scholar, 2012, S4, 722-748.	0.8	37
33	Cocaine modulates both glutaminase gene expression and glutaminase activity in the brain of cocaine-sensitized mice. Psychopharmacology, 2012, 219, 933-944.	1.5	18
34	Attenuation of cocaine-induced conditioned locomotion is associated with altered expression of hippocampal glutamate receptors in mice lacking LPA1 receptors. Psychopharmacology, 2012, 220, 27-42.	1.5	42
35	Roles of dioxins and heavy metals in cancer and neurological diseases using ROS-mediated mechanisms. Free Radical Biology and Medicine, 2010, 49, 1328-1341.	1.3	227
36	Brain glutaminases. Biomolecular Concepts, 2010, 1, 3-15.	1.0	11

#	Article	IF	Citations
37	Transfection with liverâ€type glutaminase cDNA alters gene expression and reduces survival, migration and proliferation of T98G glioma cells. Glia, 2009, 57, 1014-1023.	2.5	60
38	Glutamine homeostasis and mitochondrial dynamics. International Journal of Biochemistry and Cell Biology, 2009, 41, 2051-2061.	1.2	123
39	A novel glutaminase isoform in mammalian tissues. Neurochemistry International, 2009, 55, 76-84.	1.9	56
40	New insights into brain glutaminases: Beyond their role on glutamatergic transmission. Neurochemistry International, 2009, 55, 64-70.	1.9	33
41	Natural Antioxidants: Therapeutic Prospects for Cancer and Neurological Diseases. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1202-1214.	1.1	52
42	Intracellular redox status and oxidative stress: implications for cell proliferation, apoptosis, and carcinogenesis. Archives of Toxicology, 2008, 82, 273-299.	1.9	387
43	Expression of the scaffolding PDZ protein glutaminaseâ€interacting protein in mammalian brain. Journal of Neuroscience Research, 2008, 86, 281-292.	1.3	40
44	Antisense glutaminase inhibition modifies the Oâ€GlcNAc pattern and flux through the hexosamine pathway in breast cancer cells. Journal of Cellular Biochemistry, 2008, 103, 800-811.	1.2	43
45	Probing the Structure and Function of Human Glutaminase-Interacting Protein: A Possible Target for Drug Design. Biochemistry, 2008, 47, 9208-9219.	1.2	17
46	Expression of functional human glutaminase in baculovirus system: Affinity purification, kinetic and molecular characterization. International Journal of Biochemistry and Cell Biology, 2007, 39, 765-773.	1.2	39
47	Glutaminase: A multifaceted protein not only involved in generating glutamate. Neurochemistry International, 2006, 48, 465-471.	1.9	69
48	Pathways from glutamine to apoptosis. Frontiers in Bioscience - Landmark, 2006, 11, 3164.	3.0	60
49	Identification of genes downregulated in tumor cells expressing antisense glutaminase mRNA by differential display. Cancer Biology and Therapy, 2006, 5, 54-58.	1.5	11
50	S-nitrosothiols regulate cell-surface pH buffering by airway epithelial cells during the human immune response to rhinovirus. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 290, L827-L832.	1.3	17
51	Co-expression of glutaminase K and L isoenzymes in human tumour cells. Biochemical Journal, 2005, 386, 535-542.	1.7	104
52	Inhibition of glutaminase expression increases Sp1 phosphorylation and Sp1/Sp3 transcriptional activity in Ehrlich tumor cells. Cancer Letters, 2005, 218, 91-98.	3.2	12
53	Sensitisation of Ehrlich ascitic tumour cells to methotrexate by inhibiting glutaminase. Anticancer Research, 2005, 25, 3315-20.	0.5	5
54	Granule Localization of Glutaminase in Human Neutrophils and the Consequence of Glutamine Utilization for Neutrophil Activity. Journal of Biological Chemistry, 2004, 279, 13305-13310.	1.6	44

#	Article	IF	Citations
55	Antisense glutaminase inhibition decreases glutathione antioxidant capacity and increases apoptosis in Ehrlich ascitic tumour cells. FEBS Journal, 2004, 271, 4298-4306.	0.2	118
56	Expression of recombinant human l-glutaminase in Escherichia coli: polyclonal antibodies production and immunological analysis of mouse tissues. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2003, 1648, 17-23.	1.1	13
57	Genomic organization and transcriptional analysis of the human l-glutaminase gene. Biochemical Journal, 2003, 370, 771-784.	1.7	29
58	Nuclear Localization of L-type Glutaminase in Mammalian Brain. Journal of Biological Chemistry, 2002, 277, 38939-38944.	1.6	77
59	Corrigendum to: The C-terminus of human glutaminase L mediates association with PDZ domain-containing proteins (FEBS 24464). FEBS Letters, 2002, 531, 570-570.	1.3	1
60	Glutamine and its relationship with intracellular redox status, oxidative stress and cell proliferation/death. International Journal of Biochemistry and Cell Biology, 2002, 34, 439-458.	1.2	281
61	Overexpression, Purification, and Characterization of Glutaminase-Interacting Protein, a PDZ-Domain Protein from Human Brain. Protein Expression and Purification, 2001, 23, 411-418.	0.6	13
62	The C-terminus of human glutaminase L mediates association with PDZ domain-containing proteins 1. FEBS Letters, 2001, 488, 116-122.	1.3	56
63	Ehrlich ascites tumor cells expressing anti-sense glutaminase mRNA lose their capacity to evade the mouse immune system. International Journal of Cancer, 2001, 91, 379-384.	2.3	6
64	Ehrlich ascites tumor cells expressing antiâ€sense glutaminase mRNA lose their capacity to evade the mouse immune system. International Journal of Cancer, 2001, 91, 379-384.	2.3	26
65	Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells. Biochemical Journal, 2000, 348, 257-261.	1.7	119
66	Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells. Biochemical Journal, 2000, 348, 257.	1.7	42
67	Molecular cloning, sequencing and expression studies of the human breast cancer cell glutaminase. Biochemical Journal, 2000, 345, 365-375.	1.7	79
68	Ehrlich ascites tumour unbalances splenic cell populations and reduces responsiveness of T cells to Staphylococcus aureus enterotoxin B stimulation. Immunology Letters, 2000, 74, 111-115.	1.1	80
69	Identification of two human glutaminase loci and tissue-specific expression of the two related genes. Mammalian Genome, 2000, 11, 1107-1110.	1.0	146
70	Molecular cloning, sequencing and expression studies of the human breast cancer cell glutaminase. Biochemical Journal, 2000, 345, 365.	1.7	36
71	Upregulation of glyceraldehyde-3-phosphate dehydrogenase mRNA in the spleen of tumor-bearing mice. Biochimie, 1999, 81, 1109-1113.	1.3	4
72	Involvement of essential cysteine and histidine residues in the activity of isolated glutaminase from tumour cells. BBA - Proteins and Proteomics, 1998, 1429, 275-283.	2.1	11

#	Article	IF	Citations
73	Early differential expression of two glutaminase mRNAs in mouse spleen after tumor implantation. Cancer Letters, 1998, 133, 95-99.	3.2	8
74	Early tumor effect on splenic Th lymphocytes in mice. FEBS Letters, 1997, 414, 1-6.	1.3	43
75	Submitochondrial localization and membrane topography of Ehrlich ascitic tumour cell glutaminase. Biochimica Et Biophysica Acta - Biomembranes, 1997, 1323, 173-184.	1.4	31
76	Polyamine contents of human breast cancer cells treated with the cytotoxic agents chlorpheniramine and dehydrodidemnin B. Cancer Letters, 1997, 113, 141-144.	3.2	17
77	Identification of a Zn2 -sensitive component of Ehrlich cell plasma membrane redox system by CHAPS-agarose-polyacrylamide electrophoresis and in situ staining of activity. IUBMB Life, 1997, 41, 75-81.	1.5	1
78	Effects of protein kinase C and phosphoprotein phosphatase modulators on Ehrlich cell plasma membrane redox system activity. Biochimica Et Biophysica Acta - Molecular Cell Research, 1996, 1313, 157-160.	1.9	9
79	Purification and characterization of a plasma membrane ferricyanide-utilizing NADH dehydrogenase from Ehrlich tumour cells. Biochemical Journal, 1996, 314, 587-593.	1.7	14
80	Ehrlich cell plasma membrane redox system is modulated through signal transduction pathways involvingcGMP and Ca2+ as second messengers. Journal of Bioenergetics and Biomembranes, 1995, 27, 605-611.	1.0	14
81	Tumor Glutaminase Purification. Protein Expression and Purification, 1995, 6, 343-351.	0.6	17
82	Characterization of plasma membrane redox activity from ehrlich cells. Cell Biochemistry and Function, 1994, 12, 149-152.	1.4	6
83	Involvement of essential histidine residue(s) in the activity of Ehrlich cell plasma membrane NADH-ferricyanide oxidoreductase. Biochimica Et Biophysica Acta - Biomembranes, 1994, 1190, 20-24.	1.4	12
84	Phosphate-activated glutaminase expression during tumor development. FEBS Letters, 1994, 341, 39-42.	1.3	51
85	Native polyacrylamide gel electrophoresis of membrane proteins: Glutaminase detection afterin situ specific activity staining. Electrophoresis, 1993, 14, 88-93.	1.3	18
86	Two Phases Of Ferricyanide Reductase Activity In Ehrlich Cell Plasma Membranes. Zeitschrift Fur Naturforschung - Section C Journal of Biosciences, 1992, 47, 929-931.	0.6	6
87	Relevance of glutamine metabolism to tumor cell growth. Molecular and Cellular Biochemistry, 1992, 113, 1-15.	1.4	177
88	Interchange of amino acids between tumor and host. Biochemical Medicine and Metabolic Biology, 1992, 48, 1-7.	0.7	29
89	Simultaneous fluoremetric determination of intracellular polyamines separated by reversed-phase high-performance liquid chromatography. Agents and Actions, 1992, 36, 17-21.	0.7	26
90	Mouse liver free amino acids during the development of Ehrlich ascites tumour. Cancer Letters, 1991, 58, 221-224.	3.2	16

#	Article	IF	Citations
91	Sodium-dependentl-serine transport in plasma membrane vesicles isolated from Ehrlich cells by two-phase compartmentation. Journal of Membrane Biology, 1991, 123, 247-254.	1.0	9
92	Covalent modification of a critical sulfhydryl group in the acetylcholine receptor: cysteine-222 of the .alpha.-subunit. Biochemistry, 1989, 28, 7433-7439.	1.2	23
93	Nitrogen metabolism in tumor bearing mice. Archives of Biochemistry and Biophysics, 1989, 268, 667-675.	1.4	78
94	Altered ornithine metabolism in tumor-bearing mice. Life Sciences, 1989, 45, 1877-1884.	2.0	17
95	Interaction of nicotinic acetylcholine receptor with two monoclonal antibodies recognizing different epitopes. Biochemistry, 1989, 28, 4222-4229.	1.2	17